Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Sun, Xiaoke ^a   Liu, Zhe ^b   Yang, Zhen ^a   Xiao, Lin ^a   Wang, Feng ^a   He, Yang ^a   Su, Pengxiao ^a   Wang, Junhu ^a   Jing, Baoli ^a  

^a XI'AN HONGHUI HOSPITAL   (China)

^b STATE GRID CORPORATION OF CHINA   (China)

Author keywords

Clinical pathology; MicroRNA 126; Prognosis; Prostate cancer

Indexed keywords

KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 3, HUMAN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; MICRORNA; MIRN126 MICRORNA, HUMAN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; CANCER GRADING; CANCER STAGING; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; DOWN REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; METHODOLOGY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; PROSTATECTOMY; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TIME; TREATMENT OUTCOME;

AGED; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MICRORNAS; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890336316     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-208     Document Type: Article

References (33)

1. Parnes HL, House MG, Tangrea JA. Prostate cancer prevention: strategies for agent development. Curr Opin Oncol 2013, 25:242-251.
2. MacVicar GR, Hussain MH. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. Curr Opin Oncol 2013, 25:252-260.
3. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013, 1:CD004720.
4. Martin DN, Starks AM, Ambs S. Biological determinants of health disparities in prostate cancer. Curr Opin Oncol 2013, 25:235-241.
5. Ishizaki F, Hara N, Koike H, Kawaguchi M, Tadokoro A, Takizawa I, Nishiyama T, Takahashi K, Hohenfellner R. Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study. Diagn Pathol 2012, 7:68. 10.1186/1746-1596-7-68, 3449198, 22697234.
6. Dabir PD, Ottosen P, Høyer S, Hamilton-Dutoit S. Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma. Diagn Pathol 2012, 7:81. 10.1186/1746-1596-7-81, 3434074, 22800084.
7. Humphrey PA, Vollmer RT. Percentage of carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 1997, 10:326-333.
8. Montironi R, Mazzuccheli R, Scarpelli M, Lopez-Beltran A, Fellegara G, Algaba F. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 2005, 95:1146-1152. 10.1111/j.1464-410X.2005.05540.x, 15877724.
9. Wilt TJ, Ahmed HU. Prostate cancer screening and the management of clinically localized disease. BMJ 2013, 346:f325. 10.1136/bmj.f325, 23360718.
10. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol 2011, 38:724-733. 10.1053/j.seminoncol.2011.08.006, 22082758.
11. Sempere LF. Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn 2011, 11:813-827. 10.1586/erm.11.69, 3220160, 22022944.
12. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA Profiling of Prostate Cancer. J Cancer Educ 2013, 4:350-357.
13. Mavridis K, Stravodimos K, Scorilas A. Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem 2013, 59:261-269. 10.1373/clinchem.2012.191502, 23136246.
14. de Giorgio A, Castellano L, Krell J, Stebbing J. Crosstalk-induced loss of miR-126 promotes angiogenesis. Oncogene 2013, In press.
15. Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y, Zhou J, Hu J, Jiang B. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep 2013, 30:1976-1984.
16. Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer 2013, 81:388-396. 10.1016/j.lungcan.2013.05.007, 23756108.
17. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, Amadori D, Lu X, Xie D, Li QJ, Wang XF. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol 2013, 15:284-294. 10.1038/ncb2690, 3672398, 23396050.
18. Banerjee N, Kim H, Talcott S, Mertens-Talcott S. Pomegranate Polyphenolics Suppressed Azoxymethane-Induced Colorectal Aberrant Crypt Foci (ACF) and Inflammation: possible role of miR-126/VCAM-1 and miR-126/PI3K/AKT/mTOR. Carcinogenesis 2013, In press.
19. Sasahira T, Kurihara M, Bhawal UK, Ueda N, Shimomoto T, Yamamoto K, Kirita T, Kuniyasu H. Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer 2012, 107:700-706. 10.1038/bjc.2012.330, 3419968, 22836510.
20. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 2009, 379:726-731. 10.1016/j.bbrc.2008.12.098, 19116145.
21. Molitierno J, Evans A, Mohler JL, Wallen E, Moore D, Pruthi RS. Characterization of biochemical recurrence after radical prostatectomy. Urol Int 2006, 77:130-134. 10.1159/000093906, 16888417.
22. Hua X, Yu L, Pan W, Huang X, Liao Z, Xian Q, Fang L, Shen H. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol 2012, 7:127. 10.1186/1746-1596-7-127, 3488508, 23006319.
23. Jonsson L, Gaber A, Ulmert D, Uhlén M, Bjartell A, Jirström K. High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. Diagn Pathol 2011, 6:91. 10.1186/1746-1596-6-91, 3195697, 21955582.
24. Xu JQ, Liu P, Si MJ, Ding XY. MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1. Tumour Biol 2013, In press.
25. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008, 15:272-284. 10.1016/j.devcel.2008.07.008, 2604134, 18694566.
26. Liu B, Peng XC, Zheng XL, Wang J, Qin YW. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 2009, 66:169-175. 10.1016/j.lungcan.2009.01.010, 19223090.
27. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh DA, Johnson RS. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-818. 10.1038/nature07445, 3103772, 18997773.
28. Meister J, Schmidt MH. miR-126 and miR-126*: new players in cancer. Sci World J 2010, 10:2090-2100.
29. Ishihara K, Sasaki D, Tsuruda K, Inokuchi N, Nagai K, Hasegawa H, Yanagihara K, Kamihira S. Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol 2012, 36:560-565. 10.1016/j.canep.2012.07.002, 22884882.
30. Yu T, Wang XY, Gong RG, Li A, Yang S, Cao YT, Wen YM, Wang CM, Yi XZ. The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res 2009, 28:64. 10.1186/1756-9966-28-64, 2687417, 19435529.
31. Huang TH, Chu TY. Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer. Oncogene 2013, In press.
32. Chen H, Miao R, Fan J, Han Z, Wu J, Qiu G, Tang H, Peng Z. Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma. Clin Exp Metastasis 2013, 30:651-658. 10.1007/s10585-013-9569-6, 23378255.
33. Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K, Yuasa Y. MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS One 2011, 6:e16617. 10.1371/journal.pone.0016617, 3029394, 21304604.